Ligand Pharmaceuticals LGND Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues and income by Product | ||||||
| Captisol | $8.65M-35.7% | $7.79M-1.5% | $10.67M+70.6% | $8.29M+10.5% | $13.46M+46.1% | |
| Capvaxive | $1.97M+122% | $3.72M+1,847% | $3.21M+637% | $2.25M— | $885K— | |
| Contract revenue | $110K-97.5% | $60.43M+2,873% | $131K-99.1% | $1.93M— | $4.38M— | |
| Filspari | $11.32M+114% | $11.01M+131% | $9.08M+183% | $6.58M+171% | $5.3M+199% | |
| Kyprolis | $6.74M+42.7% | —— | $11.62M+0.2% | $8.8M-2.2% | $4.72M-28.8% | |
| Ohtuvayre inventors | $3.05M— | —— | —— | —— | $0— | |
| Ohtuvayre | $2.99M+112% | —— | —— | —— | $1.41M— | |
| Other | $3.76M+2.5% | —— | $3.42M+98.3% | $5.43M+171% | $3.67M+68.7% | |
| Qarziba | $6.3M+15.7% | $6.44M-0.9% | $5.98M+29.1% | $5.89M— | $5.44M— | |
| Rylaze | $3.22M+3.3% | —— | $3.56M-8.5% | $2.86M-11.4% | $3.12M+5.7% | |
| Teriparatide injection | $1.32M+10.9% | —— | $2.63M+10.8% | $2.3M+9.3% | $1.19M-41.6% | |
| Vaxneuvance | $1.61M+25.3% | $1.44M+17.5% | $2.04M+39.1% | $2.64M+138% | $1.29M-7.4% | |
| Total revenue and income by Product | ||||||
| Rylaze | $3.22M+3.3% | $3.81M+3.7% | $3.56M-8.5% | $2.86M-11.4% | $3.12M+5.7% | |
| Teriparatide injection | $1.32M+10.9% | $2.03M+19.2% | $2.63M+10.8% | $2.3M+9.3% | $1.19M-41.6% | |
| Financial Royalty Assets, Net by Product | ||||||
| Agenus Inc. | $40.41M— | $40.41M0.0% | $40.41M— | —— | —— | |
| Qarziba | $103.24M— | $118.1M+12.6% | $111.54M— | —— | —— | |
| Gross carrying value by Product | ||||||
| Agenus Inc. | $40.82M— | $40.82M0.0% | $40.82M— | —— | —— | |
| Qarziba | $103.72M— | $118.59M+12.6% | $112.05M— | —— | —— | |
| Financial Royalty Assets, Allowance by Product | ||||||
| Agenus Inc. | $408K— | $408K0.0% | $408K— | —— | —— | |
| Qarziba | $480K— | $498K+2.9% | $517K— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ligand Pharmaceuticals break its business down?
- Ligand Pharmaceuticals (LGND) reports total revenues and income by product across 12 parts — Captisol, Capvaxive, Contract revenue, Filspari and Kyprolis. Each is extracted from the segment footnotes and tracked over time.
- Where does Ligand Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ligand Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.